Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Int J Mol Sci
2023 Sep 08;2418:. doi: 10.3390/ijms241813842.
Show Gene links
Show Anatomy links
Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac Kv4.3 (Ito) Channel Isoforms.
Rahm AK
,
Hackbarth J
,
Müller ME
,
Pfeiffer J
,
Gampp H
,
Petersenn F
,
Rivinius R
,
Frey N
,
Lugenbiel P
,
Thomas D
.
???displayArticle.abstract???
Cardiac Kv4.3 channels contribute to the transient outward K+ current, Ito, during early repolarization of the cardiac action potential. Two different isoforms of Kv4.3 are present in the human ventricle and exhibit differential remodeling in heart failure (HF). Cardioselective betablockers are a cornerstone of HF with reduced ejection fraction therapy as well as ventricular arrhythmia treatment. In this study we examined pharmacological effects of betablockers on both Kv4.3 isoforms to explore their potential for isoform-specific therapy. Kv4.3 isoforms were expressed in Xenopus laevis oocytes and incubated with the respective betablockers. Dose-dependency and biophysical characteristics were examined. HEK 293T-cells were transfected with the two Kv4.3 isoforms and analyzed with Western blots. Carvedilol (100 µM) blocked Kv4.3 L by 77 ± 2% and Kv4.3 S by 67 ± 6%, respectively. Metoprolol (100 µM) was less effective with inhibition of 37 ± 3% (Kv4.3 L) and 35 ± 4% (Kv4.3 S). Bisoprolol showed no inhibitory effect. Current reduction was not caused by changes in Kv4.3 protein expression. Carvedilol inhibited Kv4.3 channels at physiologically relevant concentrations, affecting both isoforms. Metoprolol showed a weaker blocking effect and bisoprolol did not exert an effect on Kv4.3. Blockade of repolarizing Kv4.3 channels by carvedilol and metoprolol extend their pharmacological mechanism of action, potentially contributing beneficial antiarrhythmic effects in normal and failing hearts.
Olympia-Morata Program Heidelberg University Medical School, Kaltenbach-Promotionstipendium German Heart Foundation, Cardiology-Career-Program Department of Cardiology, Heidelberg University Hospital
Figure 1. Effects of carvedilol (100 µM) on currents produced by the Kv4.3 isoform. (A,B) Representative current traces of Kv4.3 L (A) and Kv4.3 S (B) prior to (gray) and after (black) carvedilol application (50 min). (C,D) Relative peak current of Kv4.3 L (n = 8) (C) and Kv4.3 S (n = 8) (D) before, during and after the application 100 µM carvedilol. (E,F) Concentration-response curves for Kv4.3 L (n = 8–12) (IC50 = 57.1 ± 12.6 µM) (E) and Kv4.3 S (n = 8–13) (IC50 = 58.2 ± 6.2 µM) (F).
Figure 2. Effects of carvedilol (100 µM) on activation and inactivation of the Kv4.3 isoforms. (A,B) Representative current traces of Kv4.3 L (A) and S (B) evoked by the indicated voltage protocol prior to (gray) and after (black) carvedilol application (50 min). (C,D) I-V-plots for activation of Kv4.3 L (C) and Kv4.3 S (D) (n = 11). (E,F) I-V-plots for inactivation of Kv4.3 L (E) and Kv4.3 S (F) (n = 11). * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 3. Effects of carvedilol (100 µM) on the activation and inactivation of the two Kv4.3 isoforms with short depolarizing steps. (A,B) Representative current traces of Kv4.3 L (A) and S (B) induced by the indicated voltage protocol prior to (gray) and after (black) carvedilol application (50 min). (C,D) I-V plots for activation of Kv4.3 L (C) and Kv4.3 S (D) (n = 11). (E,F) I-V-plots for inactivation of Kv4.3 L (E) and Kv4.3 S (F) (n = 11). * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 4. Effects of carvedilol (100 µM) on the recovery from inactivation of the two Kv4.3 isoforms. (A,B) Representative Kv4.3 L (A) and Kv4.3 S (B) current traces of induced by the indicated voltage protocol prior to (gray) and after (black) carvedilol application (50 min). (C,D) Recovery from inactivation curves were calculated by plotting peak current amplitudes against the duration of the preceding repolarizing step for Kv4.3 L (C) and Kv4.3 S (D) (n = 10). * p < 0.05, ** p < 0.01.
Figure 5. Effects of carvedilol (100 µM) on deactivation of Kv4.3 isoforms. (A,B) Representative current traces of Kv4.3 L (A) and Kv4.3 S (B) induced by indicated voltage protocol prior to (gray) and after (black carvedilol application (50 min)). (C,D) Deactivation time constants for Kv4.3 L (C) and Kv4.3 S (D) (n = 11). *** p < 0.001.
Figure 6. Effects of bisoprolol (100 µM) on Kv4.3 isoforms. (A,B) Representative Kv4.3 L (A) and Kv4.3 S (B) current traces of prior to (gray) and after (black) bisoprolol application (50 min). (C,D) Relative peak current carried by Kv4.3 L (n = 11) (C) or Kv4.3 S (n = 9) (D) during application of 100 µM bisoprolol.
Figure 7. Effects of metoprolol (100 µM) on Kv4.3 currents. (A,B) Representative Kv4.3 L (A) and Kv4.3 S (B) current traces of prior to (gray) and after (black) metoprolol application (50 min). (C,D) Relative peak currents of Kv4.3 L (n = 9) (C) and Kv4.3 S (n = 9) (D) before, during and after application of 100 µM metoprolol. (E,F) Concentration-response curves for Kv4.3 L (n = 9–11) (IC50 = 47.3 ± 34.2 µM) (E) and Kv4.3 S (n = 9–11) (IC50 = 49.8 ± 0.7 µM) (F).
Figure 8. Effects of betablockers on Kv4.3 isoform expression in HEK-293T cells. (A) Representative Western blots after transfection with Kv4.3 L (A) or Kv4.3 S (B) before and after incubation with respective betablockers (100 µM) for 24 h (n = 6 each). (C,D) Protein quantification of Kv4.3 L (C) and Kv4.3 S (D) protein relative to respective controls and normalized to GAPDH.
Ahmed,
Perspective on the Role of Four Beta-blockers in Heart Failure.
2022, Pubmed
Ahmed,
Perspective on the Role of Four Beta-blockers in Heart Failure.
2022,
Pubmed
Aqil,
Comparative bioavailability of metoprolol tartrate after oral and transdermal administration in healthy male volunteers.
2007,
Pubmed
Atwood,
Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis.
2011,
Pubmed
Ayan,
A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators.
2019,
Pubmed
Beuckelmann,
Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure.
1993,
Pubmed
Burke,
Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers.
2001,
Pubmed
Buś-Kwaśnik,
Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers.
2017,
Pubmed
Dixon,
Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current.
1996,
Pubmed
Dutta,
Dose proportionality of bisoprolol enantiomers in humans after oral administration of the racemate.
1994,
Pubmed
El-Sherif,
Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent?
2005,
Pubmed
Garimella,
Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
2018,
Pubmed
Gehr,
The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
1999,
Pubmed
Giudicessi,
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome.
2011,
Pubmed
Hayes,
Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease.
1987,
Pubmed
Janse,
Electrophysiological changes in heart failure and their relationship to arrhythmogenesis.
2004,
Pubmed
Karle,
Antiarrhythmic drug carvedilol inhibits HERG potassium channels.
2001,
Pubmed
,
Xenbase
Kawakami,
Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.
2006,
Pubmed
Kendall,
A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.
1980,
Pubmed
Kendall,
Metoprolol pharmacokinetics and the oral contraceptive pill.
1982,
Pubmed
Kiehn,
Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
1999,
Pubmed
,
Xenbase
Kim,
Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study.
2015,
Pubmed
Kirch,
Interaction of bisoprolol with cimetidine and rifampicin.
1986,
Pubmed
Kirch,
Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
1987,
Pubmed
Kisselbach,
Modulation of K2P 2.1 and K2P 10.1 K(+) channel sensitivity to carvedilol by alternative mRNA translation initiation.
2014,
Pubmed
,
Xenbase
Kong,
Isolation and characterization of the human gene encoding Ito: further diversity by alternative mRNA splicing.
1998,
Pubmed
Krauwinkel,
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
2014,
Pubmed
Kääb,
Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density.
1998,
Pubmed
Li,
Transmural action potential and ionic current remodeling in ventricles of failing canine hearts.
2002,
Pubmed
Li,
Bisoprolol reverses down-regulation of potassium channel proteins in ventricular tissues of rabbits with heart failure.
2011,
Pubmed
Li,
Kv4.2 phosphorylation by PKA drives Kv4.2-KChIP2 dissociation, leading to Kv4.2 out of lipid rafts and internalization.
2022,
Pubmed
McDonagh,
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
2021,
Pubmed
NULL,
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
1999,
Pubmed
NULL,
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
1999,
Pubmed
Ohya,
Molecular cloning and tissue distribution of an alternatively spliced variant of an A-type K+ channel alpha-subunit, Kv4.3 in the rat.
1997,
Pubmed
Olesen,
A novel KCND3 gain-of-function mutation associated with early-onset of persistent lone atrial fibrillation.
2013,
Pubmed
Packer,
Effect of carvedilol on survival in severe chronic heart failure.
2001,
Pubmed
Packer,
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
2006,
Pubmed
Pfannenstiel,
Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients.
1986,
Pubmed
Quarterman,
The effect of age on the pharmacokinetics of metoprolol and its metabolites.
1981,
Pubmed
Radicke,
Functional modulation of the transient outward current Ito by KCNE beta-subunits and regional distribution in human non-failing and failing hearts.
2006,
Pubmed
Rahm,
Inhibition of cardiac Kv4.3 (Ito) channel isoforms by class I antiarrhythmic drugs lidocaine and mexiletine.
2020,
Pubmed
,
Xenbase
Rahm,
PKC-dependent activation of human K(2P) 18.1 K(+) channels.
2012,
Pubmed
,
Xenbase
Rolf,
Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes.
2000,
Pubmed
,
Xenbase
Rossow,
NFATc3-induced reductions in voltage-gated K+ currents after myocardial infarction.
2004,
Pubmed
Rozanski,
Electrophysiology of rabbit ventricular myocytes following sustained rapid ventricular pacing.
1997,
Pubmed
Ruwald,
Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
2013,
Pubmed
Shen,
β-blockers augment L-type Ca2+ channel activity by targeting spatially restricted β2AR signaling in neurons.
2019,
Pubmed
Staudacher,
Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels.
2011,
Pubmed
,
Xenbase
Stout,
The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics.
2010,
Pubmed
Tenero,
Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure.
2000,
Pubmed
Tjandrawinata,
Bioequivalence study of two formulations of bisoprolol fumarate film-coated tablets in healthy subjects.
2012,
Pubmed
Tsuji,
Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle.
2000,
Pubmed
Turpault,
Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
2009,
Pubmed
Walmsley,
mRNA expression levels in failing human hearts predict cellular electrophysiological remodeling: a population-based simulation study.
2013,
Pubmed
Wang,
Time- and voltage-dependent components of Kv4.3 inactivation.
2005,
Pubmed
,
Xenbase
Werner,
Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.
2003,
Pubmed
do Carmo Borges,
Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study.
2005,
Pubmed